• Je něco špatně v tomto záznamu ?

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

AP. Stoian, N. Papanas, M. Prazny, AA. Rizvi, M. Rizzo,

. 2020 ; 25 (6) : 494-496. [pub] 20200703

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027685

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COVID-19 severity and mortality, and accumulating evidence suggests that IBTs may favorably alter the clinical course of SARS-CoV-2 infection due to their inherent mechanisms of action. Further research into prognostic variables associated with various antidiabetic treatment regimens, and in particular the IBT, in patients with T2DM affected by the COVID-19 pandemic is therefore warranted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027685
003      
CZ-PrNML
005      
20210114152227.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1074248420937868 $2 doi
035    __
$a (PubMed)32618198
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Stoian, Anca Pantea $u Diabetes, Nutrition and Metabolic Diseases Department, 87267"Carol Davila" University of Medicine, Bucharest, Romania.
245    10
$a Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights / $c AP. Stoian, N. Papanas, M. Prazny, AA. Rizvi, M. Rizzo,
520    9_
$a The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COVID-19 severity and mortality, and accumulating evidence suggests that IBTs may favorably alter the clinical course of SARS-CoV-2 infection due to their inherent mechanisms of action. Further research into prognostic variables associated with various antidiabetic treatment regimens, and in particular the IBT, in patients with T2DM affected by the COVID-19 pandemic is therefore warranted.
650    _2
$a Betacoronavirus $7 D000073640
650    _2
$a COVID-19 $7 D000086382
650    _2
$a koronavirové infekce $x farmakoterapie $x epidemiologie $7 D018352
650    _2
$a diabetes mellitus 2. typu $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a inhibitory dipeptidylpeptidasy 4 $x farmakologie $x terapeutické užití $7 D054873
650    _2
$a receptor pro glukagonu podobný peptid 1 $x metabolismus $7 D000067757
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $7 D007004
650    _2
$a inkretiny $x farmakologie $x terapeutické užití $7 D054795
650    _2
$a mediátory zánětu $x metabolismus $7 D018836
650    _2
$a pandemie $7 D058873
650    _2
$a virová pneumonie $x farmakoterapie $x epidemiologie $7 D011024
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Papanas, Nikolaos $u Diabetes Center, Second Department of Internal Medicine, 387479Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
700    1_
$a Prazny, Martin $u Third Department of Internal Medicine, First Faculty of Medicine, 37740Charles University, Prague, Czech Republic.
700    1_
$a Rizvi, Ali A $u Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, 1371Emory University, Atlanta, GA, USA. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, SC, USA.
700    1_
$a Rizzo, Manfredi $u Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, SC, USA. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), 18998University of Palermo, Italy.
773    0_
$w MED00205904 $t Journal of cardiovascular pharmacology and therapeutics $x 1940-4034 $g Roč. 25, č. 6 (2020), s. 494-496
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32618198 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152225 $b ABA008
999    __
$a ok $b bmc $g 1608020 $s 1118865
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 25 $c 6 $d 494-496 $e 20200703 $i 1940-4034 $m Journal of cardiovascular pharmacology and therapeutics $n J Cardiovasc Pharmacol Ther $x MED00205904
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace